Form 4: Altimmune CMO Buys Shares via ESPP

Altimmune's Chief Medical Officer, Matthew Scott Harris, acquired 2,018 shares of common stock through the company's Employee Stock Purchase Plan at a discounted price of $3.14 per share.

Summary

• Matthew Scott Harris, Altimmune's Chief Medical Officer, acquired 2,018 shares of Altimmune common stock.
• The shares were purchased at a price of $3.14 per share.
• This acquisition was made through the company's 2019 Employee Stock Purchase Plan (ESPP).
• The purchase price represents 85% of the closing price of Altimmune's common stock, as per the ESPP terms.
• The transaction date was July 31, 2025, covering the ESPP purchase period from February 1, 2025, to July 31, 2025.
• Following this transaction, Matthew Scott Harris directly owns 16,087 shares and indirectly owns 67,787 shares through the Matthew Scott Harris Trust.

Sentiment

Score: 7

Explanation: The acquisition of shares by a Chief Medical Officer, even through a routine ESPP, indicates continued confidence in the company. While not a strong open-market buy, it's a positive signal of insider alignment.

Positives

• An insider, the Chief Medical Officer, is increasing their ownership stake in the company.
• The purchase was made at a discounted price of $3.14 per share through the Employee Stock Purchase Plan, indicating a benefit for employees.

Future Outlook

No forward-looking statements or guidance are provided in this insider transaction report.

Industry Context

This is a routine insider transaction, common across publicly traded companies, where an executive acquires shares through an employee benefit plan. It reflects an insider's continued investment in the company, Altimmune, which operates in the biotechnology sector.

Comparison to Industry Standards

• Employee Stock Purchase Plans (ESPPs) are a common form of employee compensation and retention across various industries, including biotechnology.
• The 85% discount on the closing price, as seen in Altimmune's ESPP, is a standard discount percentage offered in many corporate ESPPs.

Corporate Governance

Related Party Transactions

• Acquisition of 2,018 common shares by Chief Medical Officer Matthew Scott Harris through the company's 2019 Employee Stock Purchase Plan (ESPP) at a discounted price of $3.14 per share.

Stakeholder Impact

• Shareholders: Increased insider ownership can be seen as a positive signal of confidence in the company's future.
• Employees: The ESPP provides a benefit for employees to acquire company stock at a discount, fostering a sense of ownership and aligning their interests with the company's performance.

Key Dates

Recommendation

This Form 4 reports a routine insider purchase through an Employee Stock Purchase Plan (ESPP). While it shows an insider increasing their stake, ESPP transactions are typically pre-scheduled and at a discount, making them less indicative of strong conviction compared to open market purchases. It's a neutral to slightly positive signal, but not enough to warrant a change in investment recommendation based solely on this filing.

Keywords

Altimmune, ALT, insider trading, stock purchase, ESPP, Chief Medical Officer, Matthew Scott Harris, beneficial ownership